Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.61 |
| ▸ | HIF1AN | Q9NWT6 | 2/20 | 0.61 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.61 |
| ▸ | OGFOD1 | Q8N543 | 1/20 | 0.61 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.61 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.43 |
| ▸ | ASPH | Q12797 | 1/20 | 0.43 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4993693 | 0.86 | EGLN1 (0.63) | EGLN1HIF1ANEGLN3OGFOD1EGLN2 | |
| SCHEMBL4740495 | 0.85 | EGLN1 (0.65) | EGLN1HIF1ANEGLN3OGFOD1EGLN2 | |
| SCHEMBL4737673 | 0.85 | EGLN1 (0.65) | EGLN1HIF1ANEGLN3OGFOD1EGLN2 | |
| SCHEMBL4739996 | 0.84 | EGLN1 (0.61) | EGLN1HIF1ANEGLN3OGFOD1EGLN2 | |
| SCHEMBL4997472 | 0.79 | EGLN1 (0.57) | EGLN1HIF1ANEGLN3OGFOD1EGLN2 | |
| SCHEMBL4991742 | 0.77 | EGLN1 (0.54) | EGLN1HIF1ANEGLN3OGFOD1EGLN2 | |
| SCHEMBL4988651 | 0.76 | EGLN1 (0.53) | EGLN1HIF1ANEGLN3OGFOD1EGLN2 | |
| SCHEMBL4992967 | 0.76 | EGLN3 (0.57) | EGLN1HIF1ANEGLN3OGFOD1EGLN2 | |
| SCHEMBL14148091 | 0.76 | EGLN1 (0.53) | EGLN1HIF1ANEGLN3OGFOD1EGLN2 | |
| SCHEMBL1641888 | 0.76 | EGLN1 (0.69) | EGLN1HIF1ANEGLN3OGFOD1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | claimed |
| WO-2008089051-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | EGLN1 5/4885HIF1AN 1/4885EGLN3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.